Edgewise Therapeutics Inc Aktie News

– New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings  – – Ongoing pivotal trial and FDA Type C meeting provide clear path to potential sevasemten registration as the first ever therapy for Becker – – Encouraging Phase 2 observations in Duchenne define the dose and inform design for Phase 3 – –  Edgewise leadership to...

BOULDER, Colo. , June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.

BOULDER, Colo. , May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.

– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – –  On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne...

On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compiled by S&P Global Market Intelligence, its share price vaulted nearly 14% higher across the week.

Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.

The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook for Edgewise Therapeutics, Inc. remains positive with multiple catalysts rapidly approaching for EWTX stock. Key milestones include 12-week data from the CIRRUS-HCM study in 2H 2025 and a phase 3 s...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor's Business Daily.